Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 6/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19960662 | 1.00 | NAAA (0.36) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL19960657 | 1.00 | NAAA (0.36) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL20113023 | 1.00 | NAAA (0.36) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL19960659 | 0.93 | NAAA (0.39) | NAAAPPARAGRM7CSNK2BCSNK2A1 | |
| SCHEMBL19960508 | 0.85 | GRM7 (0.47) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL20112962 | 0.85 | GRM7 (0.47) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL19960656 | 0.85 | GRM7 (0.47) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL19960655 | 0.85 | GRM7 (0.47) | NAAAPPARAGRM7IDH1CSNK2B | |
| SCHEMBL25625979 | 0.80 | GRM7 (0.33) | GRM7 | |
| SCHEMBL19960658 | 0.77 | GRM7 (0.43) | GRM7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541812-B1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICALS CO (JP) | 2023-06-14 | — | — | EP | disclosed |
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-11-14 | — | — | US | disclosed |
| WO-2018092921-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7- REGULATED DISEASES, DISORDERS, OR CONDITIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018079862-A1 | MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11465994-B2 | MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions | GRM7, GRM2, GRM1 | NAAA 2698/4885PPARA 1031/4885GRM7 1/4885 |
| US-20190345148-A1 | MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS | GRM7, GRM2, GRM1 | NAAA 2698/4885PPARA 1031/4885GRM7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.